Top Markets
Coin of the day
CinCor Pharma, Inc. CinCor Pharma, Inc.

CinCor Pharma, Inc.

CINC
Rank in Stocks #11593
CinCor Pharma, Inc. is an emerging biopharmaceutical firm in the clinical... CinCor Pharma, Inc. is an emerging biopharmaceutical firm in the clinical development phase, dedicated to pioneering therapeutic solutions for cardiovascular and renal conditions. At the core of its pipeline is CIN-107, an investigational compound currently undergoing Phase II clinical trials for indications such as hypertension, primary aldosteronism, and various other cardio-renal disorders. Additionally, CIN-107 is in Phase I clinical evaluation for its potential in treating chronic kidney diseases. The company holds a significant licensing agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. Established in 2018, CinCor Pharma, Inc. maintains its principal operations in Boston, Massachusetts.
Share Price
$29.06
Last synced: 2023-02-23
Market Cap
$682.73M
Change (1 day)
-0.48%
Change (1 year)
0.00%
Country
US
Trade CinCor Pharma, Inc. (CINC)

Category

Operating Margin for CinCor Pharma, Inc. (CINC)
Operating Margin as of 2026 TTM: 0.00%
According to CinCor Pharma, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for CinCor Pharma, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
38.59% -
US
28.81% -
NL
25.72% -
AU
-149.01% -
US
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.